Drug Insights

Accessing Fluconazole Information on Synapse: A Step-by-Step Approach

11 February 2024
2 min read

Fluconazole is a small molecule drug used to treat various fungal infections. It is sold under the trade names Diflucan, Zoltec, and Loitin. Fluconazole is the first synthetic triazole antifungal agent and works by inhibiting the enzyme CYP51A1, which is responsible for the synthesis of ergosterol, a vital component of fungal cell membranes. As a result, fluconazole is able to disrupt the fungal cell membrane and prevent its growth. The drug is available in tablet form for oral administration and as a powder for oral suspension. Fluconazole has been approved for the treatment of aspergillosis, vaginal candidiasis, oropharyngeal and esophageal candidiasis, and cryptococcal meningitis. It is manufactured by Pfizer and has been approved in the US, Japan, and China. Fluconazole is a white crystalline solid that is slightly soluble in water and saline. Click on the image below to begin the exploration journey of Fluconazole through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Halia Therapeutics Revels $30M Series C Funding for Inflammation Treatments
Latest Hotspot
3 min read
Halia Therapeutics Revels $30M Series C Funding for Inflammation Treatments
11 February 2024
Halia Therapeutics has unveiled a $30 million Series C funding round to further develop their innovative range of treatments for inflammation.
Read →
Maximize Your Synapse Use: Your Guide to Searching Meclizine
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Meclizine
11 February 2024
Meclizine is a small molecule drug that acts as an antagonist of histamine (H1) receptors.
Read →
Bio-Thera Solutions Initiates Phase 1B/2A Study for BAT6026 Monoclonal Antibody in Eczema Treatment
Latest Hotspot
3 min read
Bio-Thera Solutions Initiates Phase 1B/2A Study for BAT6026 Monoclonal Antibody in Eczema Treatment
9 February 2024
Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.
Read →
Master Rosuvastatin Search on Synapse
Drug Insights
2 min read
Master Rosuvastatin Search on Synapse
9 February 2024
Rosuvastatin, sold as Ezallor and Crestor, is a small molecule inhibiting liver cholesterol synthesis by blocking HMG-CoA reductase enzyme.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.